Article
Presence of MLH1 protein aggravates the potential of the HSP90 inhibitor radicicol to sensitize tumor cells to cisplatin.
International journal of oncology - 1 Dec 2005
Fedier Andre, Stuedli Angela, Fink Daniel
Abstract excerpt
MLH1 is one of five proteins crucial to DNA mismatch repair (MMR) function the loss of which is associated with a cisplatin resistance phenotype in tumor cells. An experimental approach was designed to determine whether the presence or absence of MLH1 affects the potential of radicicol to increase the sensitivity of tumor cells to cisplatin and oxaliplatin, and whether perhaps radicicol increases sensitivity to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
